Navigation Links
Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution
Date:2/18/2009

TEMPO™ for Grant Management assists medical affairs departments in deploying comprehensive investigator-initiated research grant management program

Morrisville, N.C. (PRWEB) February 18, 2009 -- Clinipace, a growing clinical research solutions company, today announced that it has been selected by two pharmaceutical firms to deploy its TEMPO™ for Grant Management solution.

Life science firms are highly cognizant of the multiple pressures to be transparent and compliant in their funding of investigator initiated research (IIR), and are turning to Clinipace in increasing numbers to help them better manage this process. Funding this research is a strategic investment, and maximizing return is critical whether in the form of publications, useful data or stronger community relationships.

Funding investigator-initiated research, in the form of grants, has become an important part of the overall clinical development program, for drugs and devices. This research furthers scientific understanding of real-world clinical profile and product utilization, identifies new indications, and augments the medical literature. As a result, medical affairs departments in many life science companies have established centralized IIR grant management functions and processes.

"Clinipace offers the only software management system that enables life science firms to centralize the application and evaluation process across the portfolio, while simultaneously empowering investigators with the tools and know-how to support individual research projects, all within one software platform. This ensures visibility and success for all stakeholders," said Jeff Williams, Chief Executive Officer at Clinipace.

About Clinipace
Clinipace is an experienced clinical research solutions company providing on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver services such as EDC, ePRO, grant management, data management, monitoring, site management, and biostatistics at a 30% - 50% savings compared to similar service providers.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb2103804.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
2. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
3. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
4. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
5. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
6. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
7. Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
8. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
9. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
10. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
11. Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: